文献速递瓣膜外科先天性心脏病外科

抗血小板治疗阻断血小板辅助的金黄色葡萄球菌对生物心脏瓣膜管道的感染性

Antiplatelet therapy abrogates platelet-assisted Staphylococcus aureus infectivity of biological heart valve conduits.
PubMed 文献 · J Thorac Cardiovasc Surg · 2019-11-23

该研究探讨血小板和纤维蛋白原在人工瓣膜移植物感染性心内膜炎起始中的作用。体外灌注实验显示,牛颈静脉壁和牛心包对金黄色葡萄球菌和血小板黏附最强,细菌通过血小板αIIbβ3与纤维蛋白原结合而黏附;标准双联抗血小板治疗(阿司匹林/替格瑞洛)使血液中金黄色葡萄球菌对牛颈静脉的黏附减少3倍。

要点

  • 牛颈静脉壁和牛心包对金黄色葡萄球菌和血小板黏附最强。
  • 金黄色葡萄球菌通过血小板αIIbβ3与纤维蛋白原结合而黏附。
  • 标准双联抗血小板治疗使牛颈静脉的细菌黏附减少3倍。

核心结论

  • 血浆纤维蛋白原结合至牛颈静脉移植物促进单个血小板经αIIbβ3黏附,金黄色葡萄球菌再经血浆纤维蛋白原结合至活化血小板αIIbβ3。
  • 双联抗血小板治疗可能是预防感染性心内膜炎及其相关死亡率的现实方法。

研究设计与样本

  • 体外灌注腔实验,定量研究金黄色葡萄球菌和血小板对5种移植物组织的黏附,并辅以显微镜分析。
  • 评估标准抗血小板治疗预防金黄色葡萄球菌心内膜炎发生的作用。

主要发现

  • 牛心包显示最大的纤维蛋白原结合。
  • 血浆预包被组织灌注中,牛心包和牛颈静脉壁对金黄色葡萄球菌亲和力最大。
  • 抗凝人血灌注所有组织时,牛心包和牛颈静脉壁触发更多血小板黏附为单个血小板。
  • 血浆包被组织灌注全血并加入金黄色葡萄球菌时,细菌仅结合至黏附的血小板。
  • 标准抗血小板治疗(阿司匹林/替格瑞洛)使血液中金黄色葡萄球菌对牛颈静脉的黏附减少3倍。

关键数值与推荐

  • 血小板黏附和血小板介导的金黄色葡萄球菌募集分别需要血小板αIIbβ3和包被或可溶性纤维蛋白原,αIIbβ3拮抗剂eptifibatide可阻断这些相互作用。

临床怎么用

  • 对于植入牛颈静脉管道的患者,标准双联抗血小板治疗可能有助于预防金黄色葡萄球菌感染性心内膜炎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Although recent advances in pulmonary valve replacement have enabled excellent hemodynamics, infective endocarditis remains a serious complication, particularly for implanted bovine jugular vein (BJV) conduits. METHODS: We investigated contributions by platelets and plasma fibrinogen to endocarditis initiation on various grafts used for valve replacement. Thus, adherence of Staphylococcus aureus and platelets to 5 graft tissues was studied quantitatively in perfusion chambers, assisted by microscopic analysis. We also evaluated standard antiplatelet therapy to prevent onset of S aureus endocarditis. RESULTS: Of all tissues, bovine pericardium (BP) showed the greatest fibrinogen binding. Perfusion of all plasma-precoated tissues identified BP and BJVwall with the greatest affinity for S aureus. Perfusions of anticoagulated human blood over all tissues also triggered more platelet adhesion to BP and BJVwall as single platelets. Several controls confirmed that both S aureus and platelets were recruited on immobilized fibrinogen. In addition, perfusions (and controls) over plasma-coated tissues with whole blood, spiked with S aureus, revealed that bacteria exclusively bound to adhered platelets. Both the platelet adhesion and platelet-mediated S aureus recruitment required platelet αIIbβ3 and coated or soluble fibrinogen, respectively, interactions abrogated by the αIIbβ3-antagonist eptifibatide. Also, standard antiplatelet therapy (aspirin/ticagrelor) reduced the adherence of S aureus in blood to BJV 3-fold. CONCLUSIONS: Binding of plasma fibrinogen to especially BJV grafts enables adhesion of single platelets via αIIbβ3. S aureus then attaches from blood to (activated) bound platelet αIIbβ3 via plasma fibrinogen. Dual antiplatelet therapy appears a realistic approach to prevent endocarditis and its associated mortality.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Ditkowski B, Bezulska-Ditkowska M, Jashari R, et al. Antiplatelet therapy abrogates platelet-assisted Staphylococcus aureus infectivity of biological heart valve conduits. J Thorac Cardiovasc Surg. 2019. PMID: 31926702. doi:10.1016/j.jtcvs.2019.10.188

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。